understandable in this volatile market. Most investors foresee the economic repercussions of massive stimulus measures leading to growth in household debt, larger corporate debt and previously unthinkable levels of government debt. In January we would have seen bigger price momentum but caution is now the new reality.
- This market is in unforeseen territory - OSL has no revenue - some distance to cash flow positive.
- ONCOSIL will gain momentum as management informs market with forward plans post CE Mark.
- if there were reservations about management execution before, then the next year will tell us how much quality resides in the executive team.
Happy to stay on board.
Ann: Oncosil breakthrough device receives CE Marking approval, page-69
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(10.0%) |
Mkt cap ! $14.99M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $23.54K | 4.717M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 22748266 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5252373 | 2 |
View Market Depth
| Last trade - 15.55pm 25/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |